7922 related articles for article (PubMed ID: 20297650)
1. [Genetic markers of melanoma].
Tronov VA; Artamonov DN; Gorbacheva LB
Genetika; 2010 Feb; 46(2):168-79. PubMed ID: 20297650
[TBL] [Abstract][Full Text] [Related]
2. [A trip through the signaling pathways of melanoma].
Fensterle J
J Dtsch Dermatol Ges; 2006 Mar; 4(3):205-17. PubMed ID: 16626317
[TBL] [Abstract][Full Text] [Related]
3. Novel biomarkers in malignant melanoma.
Bosserhoff AK
Clin Chim Acta; 2006 May; 367(1-2):28-35. PubMed ID: 16480699
[TBL] [Abstract][Full Text] [Related]
4. Switch to an invasive growth phase in melanoma is associated with tenascin-C, fibronectin, and procollagen-I forming specific channel structures for invasion.
Kääriäinen E; Nummela P; Soikkeli J; Yin M; Lukk M; Jahkola T; Virolainen S; Ora A; Ukkonen E; Saksela O; Hölttä E
J Pathol; 2006 Oct; 210(2):181-91. PubMed ID: 16924594
[TBL] [Abstract][Full Text] [Related]
5. Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma.
Salti GI; Manougian T; Farolan M; Shilkaitis A; Majumdar D; Das Gupta TK
Cancer Res; 2000 Sep; 60(18):5012-6. PubMed ID: 11016620
[TBL] [Abstract][Full Text] [Related]
6. Evidence that dysregulated DNA mismatch repair characterizes human nonmelanoma skin cancer.
Young LC; Listgarten J; Trotter MJ; Andrew SE; Tron VA
Br J Dermatol; 2008 Jan; 158(1):59-69. PubMed ID: 17970804
[TBL] [Abstract][Full Text] [Related]
7. Somatic activation of KIT in distinct subtypes of melanoma.
Curtin JA; Busam K; Pinkel D; Bastian BC
J Clin Oncol; 2006 Sep; 24(26):4340-6. PubMed ID: 16908931
[TBL] [Abstract][Full Text] [Related]
8. Expression of growth arrest and DNA damage genes and DNA mismatch repair genes in snake melanomas.
Korabiowska M; Brinck U; Frye FL; Harshbarger JC; Droese M; Kaiser HE
In Vivo; 1998; 12(5):539-42. PubMed ID: 9827364
[TBL] [Abstract][Full Text] [Related]
9. Measurement of c-myc oncogene expression provides an accurate prognostic marker for acral lentiginous melanoma.
Grover R; Chana J; Grobbelaar AO; Hudson DA; Forder M; Wilson GD; Sanders R
Br J Plast Surg; 1999 Mar; 52(2):122-6. PubMed ID: 10434891
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of nm23 in primary invasive malignant melanoma is predictive of survival outcome.
McDermott NC; Milburn C; Curran B; Kay EW; Barry Walsh C; Leader MB
J Pathol; 2000 Feb; 190(2):157-62. PubMed ID: 10657013
[TBL] [Abstract][Full Text] [Related]
11. Nuclear survivin is associated with disease recurrence and poor survival in patients with cutaneous malignant melanoma.
Piras F; Murtas D; Minerba L; Ugalde J; Floris C; Maxia C; Colombari R; Perra MT; Sirigu P
Histopathology; 2007 Jun; 50(7):835-42. PubMed ID: 17543072
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
[TBL] [Abstract][Full Text] [Related]
13. IMP3: a diagnostic and prognostic biomarker in malignant melanoma.
Xu H
Expert Rev Mol Diagn; 2008 Sep; 8(5):557-8. PubMed ID: 18785801
[No Abstract] [Full Text] [Related]
14. A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype.
Boukerche H; Baril P; Tabone E; Bérard F; Sanhadji K; Balme B; Wolf F; Perrot H; Thomas L
Cancer Res; 2000 Oct; 60(20):5848-56. PubMed ID: 11059782
[TBL] [Abstract][Full Text] [Related]
15. The MAPK pathway in melanoma.
Fecher LA; Amaravadi RK; Flaherty KT
Curr Opin Oncol; 2008 Mar; 20(2):183-9. PubMed ID: 18300768
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients.
Nishizawa A; Nakanishi Y; Yoshimura K; Sasajima Y; Yamazaki N; Yamamoto A; Hanada K; Kanai Y; Hirohashi S
Cancer; 2005 Apr; 103(8):1693-700. PubMed ID: 15751018
[TBL] [Abstract][Full Text] [Related]
17. HGF induces fibronectin matrix synthesis in melanoma cells through MAP kinase-dependent signaling pathway and induction of Egr-1.
Gaggioli C; Deckert M; Robert G; Abbe P; Batoz M; Ehrengruber MU; Ortonne JP; Ballotti R; Tartare-Deckert S
Oncogene; 2005 Feb; 24(8):1423-33. PubMed ID: 15608673
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis inhibitor, survivin, in posterior uveal melanoma: comparison among primary tumors, tumors resistant to brachytherapy, tumors with liver metastases, and liver metastases.
Ben Simon GJ; Abulafia A; Pe'er J
Curr Eye Res; 2006 Mar; 31(3):251-7. PubMed ID: 16531282
[TBL] [Abstract][Full Text] [Related]
19. Prognostic signs in melanoma: state of the art.
Lomuto M; Calabrese P; Giuliani A
J Eur Acad Dermatol Venereol; 2004 May; 18(3):291-300. PubMed ID: 15096138
[TBL] [Abstract][Full Text] [Related]
20. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
